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Abstract
PURPOSE: To review the involvement of the ion transporter Na+/K+–ATPase (NaK) in the migration and prolifera-
tion of glioma cells. Preliminary studies indicate that NaK α1 subunits seem to be upregulated in a proportion of
glioblastomas but not in normal brain tissues. DESIGN: The present review focuses on (1) the natural resistance of
migrating malignant glioma cells to apoptosis, (2) autophagic cell death as an alternative to combat malignant gli-
omas, (3) the fact that reducing the levels of malignant glioma cell motility can restore proapoptotic drug sensi-
tivity, and (4) on the observation that inhibiting the NaK activity reduces both glioma cell proliferation and
migration. RESULTS: The natural ligands of the NaK are the cardiotonic steroids. A hemisynthetic derivative of
2″-oxovoruscharin (UNBS1450), a novel cardenolide, displays unique structural features, making its binding affinity
to NaK α subunits (including α1) 10 to 100 times higher than that of other cardenolides. UNBS1450 markedly de-
creases intracellular ATP concentration in glioma cells, disorganizes the actin cytoskeleton, and leads to autopha-
gic cell death in NaK α1 over-expressing glioma cells. CONCLUSIONS: Glioblastoma patients who do not respond
to chemotherapy and whose tumors over-express NaK α1 subunits could benefit from a treatment using ligands
with marked binding affinity for the NaK α1 subunit.
Neoplasia (2008) 10, 198–206
Introduction
Gliomas account for more than 50% of all primary brain tumors and
are by far the most common primary brain tumor in adults [1]. De-
spite the advances in the management of malignant gliomas, of
which glioblastomas represent the ultimate grade of malignancy, they
remain characterized by dismal prognoses [1–4]. Glioblastoma pa-
tients have a median survival expectancy of only 14 months on the
current standard treatment of surgical resection to the extent feasible,
followed by adjuvant radiotherapy plus temozolomide, given con-
comitantly with and after radiotherapy [1–3,5]. Malignant gliomas
are associated with such dismal prognoses because glioma cells can
actively migrate through the narrow extracellular spaces in the brain,
often traveling relatively long distances, making them elusive targets
for effective surgical management [1,2]. In addition, after surgical re-
section and adjuvant treatment of malignant gliomas, the residual
cancer cells peripheral to the excised lesion give rise to a recurrent
tumor, which, in more than 90% of cases, develops immediately ad-
jacent to the resection margin [2,6,7].
Clinical and experimental data have also demonstrated that inva-
sive malignant glioma cells show a decrease in their proliferation rates
and a relative resistance to apoptosis compared to the highly cellular
center of the tumor, and this may contribute to their resistance to con-
ventional proapoptotic chemotherapy and radiotherapy [2,6,7]. As re-
cently indicated by both Okada and Mak [8] and ourselves [2,9],
despite this resistance to apoptosis being closely linked to tumorigene-
sis, tumor cells can still be induced to die by nonapoptotic mechanisms,
such as necrosis, senescence, autophagy, and mitotic catastrophe. An
international clinical trial [5] has recently revealed that the addition
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of the chemotherapeutic agent temozolomide to radiation therapy in-
creases survival of patients suffering from glioblastoma. A companion
laboratory study [10] has offered hope of even greater improvements in
patient survival in the future, through the identification of a molecular
change in the tumor that will permit the prediction of the benefit of
this new combined treatment. Temozolomide may thus circumvent
part of the glioblastoma resistance to apoptosis [2,11].
Another potential means of overcoming apoptosis resistance is by
decreasing the migration of migrating glioma cells, which results in a
significant increase in the level of sensitivity of these cells to proapop-
totic drugs [2,6]. Glioma cells are self-propelled [12] and are able to
adjust their shape and volume rapidly as they invade the brain paren-
chyma. Essential to this process is the activity of chloride channels,
anion transport mechanisms [13], and aquaporins [14]. The sodium
pump is another ion transporter that, in addition to exchanging cat-
ions, is also directly involved in the migration of cancer cells in gen-
eral [15–17] and of glioma cells in particular [18–20]. The present
review emphasizes the fact that a cardenolide-mediated decrease in
sodium pump activity could be used to combat apoptosis-resistant
malignant gliomas.
Natural Resistance of Migrating Malignant
Glioma Cells to Apoptosis (Radiotherapy
and Chemotherapy)
The natural resistance of glioblastomas to radiotherapy and che-
motherapy is attributed, at least partly, to the phosphatase and tensin
homolog on chromosome ten (PTEN)/Akt/phosphatidylinositol
3-kinase (PI3K)/mammalian target of rapamycin (mTOR)/nuclear
factor–kappa B (NF-κB) pathway [2,9,21–26] (Figure 1). The activ-
ity of the PI3K/Akt pathway is often upregulated in brain tumors
due to excessive stimulation of growth factor receptors and Ras
[27,28]. The PTEN tumor suppressor gene mutations, which result
in the activation of the PI3K-dependent activation of Akt signaling
[27,29], are frequent in de novo glioblastomas [29]. Methylation of
the PTEN promoter may represent an alternate mechanism by which
PI3K signaling is increased in grade II and III gliomas as well as in
secondary glioblastomas [24]. The activation of the PI3K pathway is
associated significantly with increasing tumor grade, lower levels of
apoptosis, and an adverse clinical outcome in the case of human gli-
omas [30]. Narita et al. [31] and Choe et al. [32] suggest that the
PI3K/Akt pathway is a particularly interesting target in the case of
glioblastomas with aberrant epithelial growth factor receptor (EGFR)
expression, because the aberrant EGFR expression and abnormal
PI3K/Akt signaling also modulate the levels of migration of tumor
astrocytes [2]. A number of publications have already reported that
an aberrantly activated PI3K/Akt pathway renders tumor cells resis-
tant to cytotoxic insults, notably to anticancer drugs [33,34]. Shingu
et al. [34,35] have shown that the inhibition of this pathway restores
or even augments the effectiveness of chemotherapy on glioma cells.
PI3K inhibitors could also be used to reduce the levels of tumor as-
trocyte migration, a feature that could restore a certain level of apop-
tosis to these cells [33]. Cell survival through Akt signaling also
involves the NF-κB pathway because Akt signals to various cell death
regulators including IκB kinase, which controls NF-κB activity.
NF-κB itself plays a dramatic role in gliomagenesis [2,23]. For exam-
ple, the NF-κB signaling pathway is constitutively activated in a large
proportion of glioblastomas [36], and this activation enables cancer
cells to resist cytotoxic insults [37,38]. The constitutive activation of
Akt and NF-κB contributes significantly to the progression of diffuse
gliomas, and the activation of Akt may lead to NF-κB activation in
high-grade gliomas. As detailed below, cardenolide-induced inhibi-
tion of Na+/K+–ATPase (NaK) activity leads to the deactivation of
the NF-κB pathway.
Rapamycin inhibits the phosphorylation of the retinoblastoma pro-
tein, and rapamycin-treated glioblastoma cells are therefore not fully
committed to entering the S-phase after their release from drug-induced
G1 arrest [39,40]. Constitutive Rb phosphorylation frequently occurs
in glioblastomas due to mutation-induced p16 gene inactivation [1].
The mTOR can also control cell migration in glioblastomas [2].
Several strategies could be used potentially to overcome glioma cell
resistance to cytotoxic insults: (1) inhibition of the signaling path-
ways that are constitutively activated in a specific malignant glioma
specimen; (2) use of inhibitors to reduce the levels of tumor astrocyte
migration, a feature that could restore a certain level of apoptosis to
these cells; (3) induction of autophagic cell death as opposed to apop-
tosis; and (4) inhibition of sodium pump activity, which disorganizes
the actin cytoskeleton (reducing motility and proliferation) and in-
duces autophagic processes in malignant glioma models [2].
Autophagy: A Potential Trojan Horse for
Malignant Gliomas
Cell death can be divided into apoptotic cell death and nonapopto-
tic cell death [8]. Because glioblastoma cells carry mutations that inac-
tivate apoptotic pathways [2], nonapoptotic cell death could represent
an alternative for apoptosis-resistant glioma cells to be destroyed
[9,41]. Whereas apoptosis is a caspase-dependent process characterized
by the condensation of cytoplasm and the preservation of organelles,
essentially without any autophagic degradation, autophagic cell death
Figure 1. Pathways involved in the natural resistance of glioblas-
tomas to radio/chemotherapy. Pathways involved in cytotoxic in-
sult resistance are presented in orange. The PTEN gene mutation
or methylation promotes Akt activation. ERK indicates extracellular
signal–regulated kinase; MAPK, mitogen-activated protein kinase.
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is a caspase-independent process that exhibits extensive autophagic
degradation of the Golgi apparatus, the polyribosomes, and the en-
doplasmic reticulum (Figure 2), with all these features preceding the
destruction of the nucleus [8,9,42]. Autophagy begins with the se-
questration of cytoplasmic organelles into membrane vacuoles called
autophagosomes which then fuse with lysosomes to form autolyso-
somes, in which materials are subsequently degraded and recycled
[9,11,42] (Figure 2). The mTOR seems to be involved in autophagic
cell death as its inactivation can induce autophagy [9] (Figure 2). The
mTOR is a downstream effector of the PI3K/Akt signaling pathway,
and it is also a central modulator of cell proliferation in malignant glio-
mas [40,43]. In fact, rapid tumor proliferation (that can result from
low apoptotic levels) may contribute to the clinical resistance of glio-
blastomas to radiotherapy, and disruption of mTOR signaling by ra-
pamycin appears to return a certain level of sensitivity to resistant
glioblastoma cells [44]. Takeuchi et al. [43] showed that rapamycin
induced autophagy but not apoptosis in rapamycin-sensitive malig-
nant glioma U87-MG and T98G cells by inhibiting the function of
mTOR. In contrast, in rapamycin-resistant U373-MG cells, the inhib-
itory effect of rapamycin is minor [43].
A source of real hope in glioma chemotherapy is offered by temo-
zolomide, a second-generation imidazotetrazine-alkylating agent
[3,5,45]. Temozolomide is a small lipophilic molecule, which can
be administered orally and which crosses the blood-brain barrier ef-
fectively. Moreover, temozolomide is less toxic to the hematopoietic
progenitor cells than conventional chemotherapeutic agents and does
not require any hepatic metabolism for activation [11]. An interna-
tional clinical trial [5] has shown that the addition of temozolomide
to radiotherapy increases the survival of patients suffering from newly
diagnosed glioblastomas. Indeed, addition of temozolomide to radio-
therapy improves median survival in newly diagnosed glioblastoma
patients from 12.1 to 14.6 months, and it increases the 2-year
survival from 10.4% to 26.5% [5]. Part of temozolomide’s cytotoxic
activity is exerted through proautophagic processes, at least in glio-
blastoma cells, due to the formation of O6-methylguanine in DNA,
which mispairs with thymine during the next cycle of DNA replica-
tion [11,46]. Glioma cells thus respond to temozolomide by under-
going G2/M arrest but will ultimately die from autophagy [11,46].
Knowing that O6-alkylguanine-DNA alkyltransferase is a DNA re-
pair enzyme that limits the efficacy of temozolomide in glioblastoma
cells, Kanzawa et al. [46] showed that inhibition of O6-alkylguanine-
DNA alkyltransferase by O6-benzylguanine can render previously re-
sistant glioblastoma cells sensitive to temozolomide. Hegi et al. [10]
showed that patients who had glioblastomas that contained a meth-
ylated O6-methylguanine-DNA methyltransferase (MGMT) pro-
moter benefited from temozolomide, whereas those who did not
were less responsive. However, results contradicting these findings
are present in the literature, and the clinical and genetic context
framing MGMTmethylation is poorly characterized. Recent observa-
tions suggest that MGMTmethylation is part of the genetic signature
of glioblastomas that develop from lower-grade gliomas [47]. Part of
temozolomide’s cytotoxic activity is, however, also due to the induc-
tion of late apoptosis. Indeed, Roos et al. [48] showed that malignant
glioma cells undergo apoptosis after treatment with the methylating
agents N-methyl-N′-nitro-N-nitrosoguanidine and temozolomide.
O6-methylguanine–triggered apoptosis in gliomas is a late response
(occurring >120 hours after treatment) that requires extensive cell
proliferation. Overall, the data reported by Roos et al. [48] demon-
strate that cell death induced by temozolomide in gliomas is due to
apoptosis and that the determinants of sensitivity of gliomas to temo-
zolomide are MGMT, p53, proliferation rate, and double-strand
break repair.
The data reported by Kanzawa et al. [11] and Roos et al. [48] are
not contradictory, because autophagy and apoptosis may be triggered
by common upstream signals, and sometimes this results in com-
bined autophagy and apoptosis [49] (Figure 2). In other instances,
the cell switches between the two responses in a mutually exclusive
manner [49]. On a molecular level, this means that the apoptotic and
autophagic response machineries share common pathways that either
link or polarize the cellular responses [49] (Figure 2). We will show
below that inhibiting sodium pump activity in human apoptosis–
resistant glioblastoma cells can induce marked processes of autophagy.
Reducing Malignant Glioma Cell Motility to
Restore Proapoptotic Drug Sensitivity
For motility, cells must acquire spatial asymmetry enabling them
to turn intracellularly generated forces into net cell body transloca-
tion [2]. One characteristic of this asymmetry is a polarized morphol-
ogy, i.e., a clear distinction between the front and rear of cells. An
Figure 2. The molecular regulation of autophagy and the link with
apoptosis. In the presence of growth factors, growth factor re-
ceptor signaling activates cascades to the mTOR, resulting in
the inhibition of autophagy or type II programmed cell death
(PCD; right-hand side of the figure). In contrast, inactivation of
mTOR can induce both apoptosis and autophagy. The left-hand
side of the figure represents a simplified version of the two main
signaling pathways of apoptosis. The intrinsic pathway includes
the mitochondria. The extrinsic cell death pathway is mediated
by death receptors (DR). After formation of the DR/death-inducing
signaling complex (DISC) and recruitment of caspases, down-
stream signaling pathways lead to apoptosis.
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early event in this polarization is a change in filamentous F-actin dis-
tribution from azimuthal symmetry around the cell rim to a concen-
tration in a particular region [2]. Additional molecular rearrangements
consist of the redistribution of chemosensory signaling receptors,
integrins, and other adhesion receptors, and the redistribution of
integrin-cytoskeleton linkages [2]. Another important consequence of
polarization is that the extension of active membrane processes, includ-
ing both lamellipodia and filopodia, takes place primarily around the
cell front, so that directional turning is generally accomplished gradu-
ally, with cell locomotion taking on the character of a persistent ran-
dom walk. Lamellipodia are broad flat sheet-like structures, whereas
filopodia are thin cylindrical needle-like projections. These structures
contain an abundance of actin and actin-associated proteins [2]. The
extension of both the lamellipodia and the filopodia in response to mi-
gratory stimuli is almost universally found in conjunction with local
actin polymerization [2,50,51]. Along with a bias toward membrane
extensions at the cell front, attachments tend to form preferentially
at the leading edge of lamellipodia and filopodia [2,50,51]. Rapid mi-
gration also requires efficient mechanisms to release adhesion at the
rear [2]. Whereas the actin cytoskeleton provides the driving force at
the front, the microtubule network assumes a regulatory function in
coordinating rear retraction [2].
As indicated previously, one potential way of overcoming apoptosis
resistance is by decreasing the migration of migrating glioma cells,
which results in a net increase in the level of sensitivity of these cells
to proapoptotic drugs [2]. This concept was recently verified in vivo
after combining temozolomide with two distinct antimigratory strate-
gies. Indeed, we showed that when compared to temozolomide alone,
the therapeutic benefits obtained in vivo in experimental models of
human orthotopic glioblastomas were significantly more pronounced
when combining either cimetidine (a histamine H2 receptor antago-
nist with antiadhesive properties) [52] and temozolomide [53] or te-
mozolomide and a small interfering RNA–directed against galectin-1
[54], which is a potent modulator of glioma cell migration [55]. Simi-
lar data were obtained when we combined temozolomide with the tar-
geting of sigma1 receptors in glioblastoma cells [56].
The Sodium Pump Constitutes a New Target to
Combat Malignant Gliomas
The Sodium Pump
In mammalian cells, active sodium transport and its derived func-
tions (e.g., plasma membrane potential) are dictated by the activity of
the NaK, whose regulation is essential for maintaining cell volume
and composition, as well as other vital cell functions [57]. Because
the plasma membrane is highly permeable to water, it is the concen-
tration of ions across this membrane that is, in the short term, critical
for maintaining an adequate cell volume. The plasma membrane
NaK is important in this process because it provides the driving force
for active sodium and potassium transport into and out of the cell,
with water following isosmotically [57]. Increases in sodium perme-
ability require concomitant increments in NaK-mediated outward
sodium transport to prevent a disproportionate increase in the intra-
cellular sodium concentration/osmotic pressure and, consequently,
cell swelling (Figure 3A).
The sodium pump consists of equimolar ratios of two main sub-
units, the catalytic α and regulatory β polypeptides, each of which ex-
ists as several isoforms [17]. To date, four different α and three distinct
β isoforms have been identified in mammalian cells [17,58–60]. The
α subunit contains the binding sites for the previously mentioned cat-
ions, ATP, and cardiotonic steroid inhibitors [18,59,60]. Whereas the
β subunit is essential for the normal activity of the enzyme, it also ap-
pears to be involved in the occlusion of K+ and modulation of the
enzyme’s K+ and Na+ affinity [18,60]. In addition to pumping ions
(Na+ and K+) across the plasma membrane (Figure 3A), the sodium
pump functions as a receptor for cardiotonic steroids [17,59,60], in-
cluding ouabain, digitoxin, and digoxin, and the novel cardenolide
UNBS1450 [17,18,20] (Figure 3).
During apoptosis, there is compelling evidence indicating an early
increase in intracellular sodium followed by a decrease in both intra-
cellular K+ and Na+, suggesting a regulatory role for these cations
during both the initial signaling and the execution phase of apoptosis
[60]. Recent studies have shown that the NaK is involved in con-
trolling perturbations of Na+ and K+ homeostasis during apoptosis
and that antiapoptotic Bcl-2 and Bcl-XL molecules influence these
ionic fluxes.
Cardiotonic Steroids: Ligands of the Sodium Pump
Cardenolides and bufadienolides are the two chemical subclasses that
constitute the cardiotonic steroids [17]. The sodium pump is character-
istically inhibited by cardiac glycosides. By binding to NaK, cardiotonic
steroids elicit the activation of the so-called Na+/K +–ATPase signalosome
[17,58] (Figure 3B).
The growth of a glioma requires the destruction of the normal
brain parenchyma by the glioma cells [12]. This is achieved through
the cellular release of glutamate into the peritumoral space [61] in
the absence of functional Na+-dependent glutamate transporters in
glioma cells, resulting in the consequent accumulation of excitotoxic
glutamate in the extracellular glia space [62]. Signaling through glu-
tamate receptors is also involved in glioblastoma cell proliferation
[63]. In addition, as indicated in the Introduction, glioma cells are
self-propelled [12] and are able to adjust their shape and volume rap-
idly as they invade the brain parenchyma. Essential to this process is
the activity of Cl− channels and anion transport mechanisms [13]. As
indicated previously, NaK is an ion transporter, which, in addition to
exchanging cations, is also directly involved in the migration of can-
cer cells in general [17,18] and of glioma cells in particular [20], as
detailed in the next section. Moreover, the activity of NaK can be
modulated by glutamate and its receptors [64].
Cardenolides, such as digitalis (digitoxin and digoxin), have been
used for the treatment of congestive heart failure for more than
200 years [18]. Digoxin is still used to treat approximately 1.7 mil-
lion patients in the United States for heart failure and/or atrial fibril-
lation despite the development of newer pharmacological agents,
such as angiotensin-converting enzyme (ACE) inhibitors, angiotensin
II receptor antagonists, and β-blockers [18]. Besides its classic use in
cardiac diseases, the use of digitalis in oncology has already been pro-
posed [65–67]. As mentioned previously, the constitutive activation
of the NF-κB pathway in cancer cells leads them to become che-
moresistant [37,38]. Different types of cardenolides are able to sup-
press the constitutive activation of NF-κB [17,66,68] to induce
apoptosis [17,67] and to overcome multidrug resistance [69]. Several
cardenolides have been shown to display in vitro antitumor activities
against various types of cancer cells [17,65–68] including glioma
cells [20,69]. However, none have ever reached clinical application
because either their therapeutic index (ouabain, digitoxin) or their
antitumoral activity (digoxin) were too low. UNBS1450 is a novel
cardenolide hemisynthesized from 2″-oxovoruscharin [69], with a
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toxicity profile similar to digoxin but with significantly more marked
antitumor activity [17,70]. It displays potent antitumor activity in
human non–small cell lung cancers [68,71], especially in those can-
cers in which the NaK α1 subunit is over-expressed [17]. UNBS1450
induces nonapoptotic cell death in apoptosis-resistant cancer cells,
including lysosomal membrane permeabilization–related death in
non–small cell lung cancer cells [71] and autophagic cell death in
glioblastoma cells [20].
The Sodium Pump Is Involved in Cancer Cell Proliferation,
Migration, and Death
There are in fact two pools of the sodium pump within the plasma
membrane with two distinct functions. One constitutes the energy-
transducing pool of the enzyme broadly distributed in the plasma
membrane (Figure 3A). The other is the signal-transducing pool of
the enzyme restricted to the caveolae which is independent of changes
in intracellular Na+ and K+ concentrations [58,60] and requires the
initial association of the sodium pump with tyrosine kinase Src [72]
(Figure 3B). The NaK signalosome closely interacts with major com-
ponents of gliomagenesis, including for example, the interaction of
EGFR with caveolin-1 [60], the binding of PI3K to NaK [16], and
the involvement of Src, Ras, and EGFR in the signal-transducing func-
tion of NaK [72] (Figure 3B).
In carcinomas of epithelial origin, downregulation of β1 subunit
expression has been shown to induce an increase in the expression
of the transcription factor Snail, which is known to downregulate
E-cadherin [15] and so facilitate the spread of cancer cells from
the primary tumor [16]. The β2 isoform of the sodium pump is in
fact a homolog of the adhesion molecule on glia (AMOG) which is
a recognition element for cell adhesion that subsequently links cell
adhesion and ion transport [19,73,74]. The AMOG/β2 and the
α1 subunits of the sodium pump come together to form functional
Figure 3. The NaK functions as a receptor for cardiotonic steroid inhibitors. In addition to pumping ions (Na+ and K+) across the plasma
membrane using ATP as the driving force (A), the sodium pump in caveolae is engaged in the assembly of multiple protein complexes that
transmit signals to different intracellular compartments (B). (A) For every three Na+ ions pumped out of the cell, two K+ ions are pumped in.
The partial inhibition of the sodium pump by the cardenolide ouabain causes a modest change in [Na+]i and [K
+]i, and a significant change
in [Ca2+]i through the Na
+/Ca2+–exchanger. (B) The NaK signalosome closely interacts with major components of gliomagenesis: EGFR,
caveolin-1, PI3K, Src, and Ras. On ouabain binding, the NaK α1 subunit in caveolae associates with several proteins, such as caveolin-1
through two caveolin-binding motifs and Src through multiple domains. Activated Src secondarily trans-activates EGFR which in turn re-
cruits the adapter protein Shc to relay signals to the Ras-Raf-MAPKs cascade. In contrast, UNBS1450 at 10 nM, a concentration at which it
demonstrates potent antiproliferative and antimigratory activity, does not elicit increases in [Ca2+]i or [Na
+]i in cells but the compound
decreases ([ATP]i). Grb2 indicates growth factor receptor–bound protein 2; MEK, MAPK-ERK–activating kinase; PKC, protein kinase C;
PLC, phospholipase C; Ros, reactive oxygen species; Shc, src homology collagen–like protein; Sos, son of sevenless.
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sodium pumps [74]. The AMOG is downregulated in human and
mouse gliomas [19]. We have identified the sodium pump as a major
element in the migration of tumor cells [17,18], including glioblas-
toma cells [20] arising from its close interaction with caveolin-1 and
its role in the organization of the actin cytoskeleton in the caveolae.
We have found that the α1 subunit of the sodium pump is located at
the lamellipodia of the human glioblastoma cell line U373-MG,
where it colocalizes with caveolin-1 [20]. Caveolae functions rely
on caveolin-1, their major protein, which drives the formation of
plasma membrane caveolae and anchors them to the actin cytoskel-
eton (Figure 3B). In addition, caveolin-1 modulates cell interaction
with the extracellular matrix and brings together and regulates the
interaction of different signaling molecules, with significant roles
in cell movement [75]. Importantly, caveolin-1 depletion results in
the loss of focal adhesion sites and overall cell adhesion [75]. Further-
more, we have shown by means of quantitative reverse transcription–
polymerase chain reaction that the levels of α1 subunit mRNA are
higher in glioblastomas (7 of 10 human glioblastomas analyzed) than
in normal brain tissue (0 of 4 normal brain tissue samples) [20]. Such
measurements also revealed high levels of the α1 subunit mRNA in
human glioblastoma U373-MG cells [20].
UNBS1450: A Novel Cardiotonic Steroid That Potently
Inhibits NaK α1 Subunit Activity
We have shown that various types of cancer including glioblasto-
mas [20], non–small cell lung cancers [17] and melanomas (manu-
script in preparation) over-express the α1 subunit of the sodium
pump when compared to the normal tissues from which they arise.
However, classic cardenolides display too poor an affinity for this
subunit to make them potential antitumor agents acting through
the inhibition of NaK α1. However, UNBS1450, because of its
marked inhibitory effects on NaK α1 subunit activity [17,20], may
represent such a potential candidate. To determine the effect of the
compound on the activity of NaK isozymes, α1β1, α2β1, and α3β1,
sodium pump complexes were produced using a baculovirus expres-
sion system and dose-response curves to the compound were per-
formed [17,20]. Heterologous protein expression in insect cells was
used because it offered the advantage of a eukaryotic expression sys-
tem able to produce large amounts of active recombinant NaK iso-
zymes in a background with very little or no endogenous sodium
pump present [58]. UNBS1450 had a marked inhibitory effect on
α1β1, α2β1, and α3β1 NaK isozymes [17,20]. The calculated inhibi-
tion constants (Ki) show that the compound inhibits α1β1 with a po-
tency that is approximately 100 times greater than that of ouabain or
digoxin [17,20]. Taken together, these data suggest that the α1 sub-
unit of the sodium pump may indeed represent a potential target to
combat apoptosis-resistant proliferating, as well as, migrating glio-
blastoma cells.
UNBS1450 Displays Marked Antiproliferative Effects In Vitro
UNBS1450 has been tested in 58 distinct human cancer cell lines
and it displays antitumor effects similar to taxol [69]. It is also active
on taxol-resistant tumor cells [69]. In three distinct glioblastoma cell
lines, the in vitro antiproliferative effects of UNBS1450 are similar to
vincristin but much greater than those displayed by temozolomide,
tamoxifen, hydroxy-tamoxifen, lomustin, procarbazin, and carmustin
[20]. All of these named drugs have been evaluated with varying de-
grees of success in the treatment of patients with malignant gliomas
[2,3,76,77].
UNBS1450 is more potent in inhibiting the proliferation of U373-
MG glioblastoma cells than that of normal cells [20], a feature that
can be explained, at least in part, by the fact that (1) U373-MG glio-
blastoma cells express higher levels of NaK α1 subunits than normal
cells, (2) UNBS1450 decreases the intracellular ATP concentration
([ATP]i) more markedly in U373-MG glioblastoma cells than in nor-
mal cells, and (3) [ATP]i is higher in normal cells than in U373-MG
cancer cells [20].
UNBS1450 Contributes Significant Therapeutic Benefits
in a Human Orthotopic Glioblastoma Xenograft Diffusely
Invading the Brain Parenchyma of Immunocompromised Mice
Active doses of UNBS1450 in human cancer xenograft models
in vivo are in the 10-to-20-mg/kg range on repeat intraperitoneal
(i.p.) administration [68,70,71], whereas the acute lethal i.p. dose
is ∼120 mg/kg in mice [69]. We have also demonstrated that the
compound is active at lower repeat-dose levels after IV dose against
orthotopic human U373-MG glioblastoma xenografts [20]. The
dose used was made of the U373-MG glioblastoma model because
it displays astrocytic differentiation features [78,79], it is nondeleted
in 1p19q [78], and it behaves as a chemoresistant high-grade ma-
lignant glioma [78] in which surgery is only of limited therapeutic
benefit [80] given its diffusely invasive nature into the brains of im-
munocompromised mice [20]. In this U373-MG orthotopic xeno-
graft model, UNBS1450 contributes therapeutic benefits that are
similar or even higher than those of temozolomide [20].
Mechanism of Action of UNBS1450 in Glioblastoma Cells
Our results show that UNBS1450-mediated antiproliferative and
antimigratory effects on human glioblastoma cells occur as a result
of the disorganization of the actin cytoskeleton [20]. It should be
borne in mind that the actin cytoskeleton is involved in many cellular
processes that are essential for cell growth, differentiation, division,
membrane organization, and motility [50]. Moreover, the association
of actin filaments with the plasma membrane provides mechanical
stability, maintains cell shape and adhesion, and regulates dynamic sur-
face protrusions such as lamellipodia and filopodia, which are funda-
mental determinants of motility and migratory potential of cells [51].
As stated previously, the sodium pump is directly linked to the actin
membrane cytoskeleton through its α subunit, and UNBS1450 mark-
edly inhibits sodium pump activity (Figure 3) [69,70,81]. Furthermore,
cellular ATP depletion results in a rapid duration-dependent disso-
ciation of the sodium pump from the actin cytoskeleton [81] and in
the redistribution of F-actin from a primarily cortical concentration
to a perinuclear location [81], as observed when treating U373-MG
glioblastoma cells with UNBS1450 [20]. The potent antiproliferative
effects observed with UNBS1450 in three human glioblastoma cell
lines were not related to proapoptotic effects at concentrations rang-
ing between 10 and 1000 nM [20]. UNBS1450-induced cell death
in these human glioblastoma cell lines seemed to occur as the re-
sult of proautophagic effects [20]. Indeed, we first observed an increase
in acidic vesicular organelles (including autophagic vacuoles) in human
glioblastoma cells treated with UNBS1450. The levels of microtubule-
associated protein 1 light chain 3 and beclin-1, two specific autophagy
markers [9,11] (Figure 2), also increased in human glioblastoma cells
treated with UNBS1450 [20]. UNBS1450-induced decreases in [ATP]i
could be also responsible, at least in part, for the induction of the
autophagic processes [42,82]. Indeed, intracellular ATP depletion trig-
gers autophagy through the mTOR pathway [42].
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Novel Cardenolide Preclinical Data
Whereas UNBS1450 displays cardiovascular side effects that are
similar in vivo in dogs to digoxin, it is between 20 and 100 times
more potent against cancer cell lines in vitro [17]. The IC50 values
for the antiproliferative activity of digitoxin in vitro range between 3
and 33 nM depending on the cancer cell line used, whereas peak
concentrations in the plasma of patients with cardiac disease range
between 20 and 33 nM [83]. The antiproliferative IC50 values of
UNBS1450 range between 5 and 20 nM, however it is 10 times less
toxic than digitoxin to mice [68]. Moreover, the plasma half-life of
UNBS1450 is ∼1 to 2 hours compared to about 8 hours for digoxin.
UNBS1450 may therefore not present the potential inconvenience of
cumulative cardiotoxicity seen with digoxin. The limiting toxicity of
cardenolides is indeed their cardiotoxicity, which relates to the in-
crease in [Ca2+]i due to the cardenolide-mediated inhibition of the so-
dium pump. The increase in [Ca2+]i leads to an increase in [Na
+]i
and a decrease in the Na+ gradient that drives the function of the
Na+/Ca2+ exchanger [18]. A lower activity of the Na+/Ca2+ exchanger
results in a rise in [Ca2+]i and the positive inotropic effects of cardio-
tonic steroid [18]. It is this increase in [Ca2+]i that is also involved in
most of the adverse effects of digitalis. In contrast, UNBS1450 does
not elicit increases in [Ca2+]i or [Na
+]i in cells at its antiproliferative
and antimigratory IC50 values [17,20].
UNBS1450 is currently undergoing regulatory preclinical evalua-
tion (toxicology, safety pharmacology, drug metabolism, and pharma-
cokinetic development studies are ongoing) and should reach Phase I
clinical trials by mid 2008.
Conclusions
Malignant gliomas are associated with dismal prognoses because
they diffusely infiltrate the brain parenchyma, therefore rendering
total surgical resection of all tumor cells impossible. In addition,
those migrating glioblastoma cells that escape the most sophisticated
surgical approaches are resistant to apoptosis and thus to radiother-
apy and most chemotherapeutic agents. However, a number of strat-
egies are emerging to overcome, at least partly, the resistance of
migrating glioma cells to apoptosis. These involve (1) inhibition of
the molecular pathways involved in apoptosis resistance that are over-
expressed in glioma cells, (2) induction of autophagy, and (3) reduc-
ing malignant glioma cell migration; a process which in turn seems
to restore a certain level of sensitivity to proapoptotic cytotoxics in
migration-restricted glioma cells.
Our strategy has been to target the α1 subunit of the sodium
pump in those glioblastomas that over-express this subunit with novel,
potent, and selective cardenolides. In so doing, using UNBS1450, it
has been possible to markedly impair (at least in experimental models
of human glioblastomas) both glioblastoma cell proliferation and mi-
gration (through a disorganization of the actin cytoskeleton), with
marked features of autophagy as the terminal outcome. In essence,
the targeting of the sodium pump α1 subunit in glioblastoma cells ap-
pears to impair both their proliferation and migration, even if they are
resistant to apoptosis.
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